Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-21

Clinical Trial Update: Study of Safety of Foradil in Patients With Persistent Asthma [Phase 4]

View source ↗

Summary

A Phase 4 safety study of Foradil (formoterol) in patients with persistent asthma was terminated. Results have been posted (2017-03-21).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Foradil (formoterol)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Persistent Asthma | Phase 4 | Status: TERMINATED | Results posted: 2017-03-21